PTPRD and bladder transitional cell carcinoma: A trend towards an OS benefit was observed in PTPRD/PTPRT mutant patients with the BLCA (Supplementary Figure 2C), CRC (Supplementary Figure 2D), EAC (Supplementary Figure 2E), and HNSC (Supplementary Figure 2F), despite a statistically significant difference not being found.